Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.
about
HIV-Host Interactions: Implications for Vaccine DesignHarnessing the protective potential of HIV-1 neutralizing antibodiesDevelopment of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infectionVirological features associated with the development of broadly neutralizing antibodies to HIV-1HIV broadly neutralizing antibody targetsStructural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 DonorsMaturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic AntibodyStructures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine designNeutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptorProgress in HIV-1 vaccine development.Cross-Neutralizing Antibodies in HIV-1 Individuals Infected by Subtypes B, F1, C or the B/Bbr Variant in Relation to the Genetics and Biochemical Characteristics of the env GeneHIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimersA Little Help From the Follicles: Understanding the Germinal Center Response to Human Immunodeficiency Virus 1 Infection and Prophylactic Vaccines.Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.Free Energy Perturbation Calculation of Relative Binding Free Energy between Broadly Neutralizing Antibodies and the gp120 Glycoprotein of HIV-1.Current views on the potential for development of a HIV vaccine.Lessons learned from human HIV vaccine trials.Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals.Early development of broadly neutralizing antibodies in HIV-1-infected infantsAntibody 10-1074 suppresses viremia in HIV-1-infected individualsTransplanting supersites of HIV-1 vulnerability.Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimerCooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies.Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodiesGlobal panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodiesHIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success.Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies.Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies.Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.Stapled HIV-1 peptides recapitulate antigenic structures and engage broadly neutralizing antibodies.A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component.Structure and immune recognition of trimeric pre-fusion HIV-1 Env.Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual.Antibodies for prevention of mother-to-child transmission of HIV-1HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and PotencyHuman immunodeficiency virus vaccinesDifferences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa.Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research
P2860
Q26765966-5A4BE670-56EF-4ACA-BEBF-7C94BCF834E7Q26766153-E6433D67-4206-470B-81DA-49F06E5CCE9DQ27022652-4CDE37DC-CEF5-4D9B-BB47-0E831186376AQ27025177-E285D76B-900E-4977-89B9-A57440AED9B1Q27026662-7076B2A2-0635-4CD6-BBF1-AA998B686BDBQ27643993-0D33B86D-BB2A-495F-ADA0-EE106C558A25Q27644415-762C9086-E865-429B-8E6B-A120FFCB26FAQ27644634-1A3C65D0-FEE0-447C-AF92-24F76748CFCDQ27684529-85F4AEA5-063A-47A1-80C2-6D1253943D4DQ27693849-CB6514D4-7380-48FE-AE00-6059B15547A6Q28554907-6554CF86-C8A2-4FDB-A1B1-3BDCB412BA88Q28647225-71A6F4E7-4AE5-48E5-9BD0-0660CD8BA452Q30234577-9F220645-7B5F-4F71-8129-B8B3EFF9548FQ30234773-EF66F3B8-420A-487B-A901-67B1833834F5Q30395868-086B9231-18DF-4A57-95AA-8DA96D4B417CQ30397595-035B0126-884A-43FC-9A8B-3DC17F958059Q33557844-8D7D816F-FBD8-4E09-B3F7-0F1C62548E3AQ33594304-3A2405E5-BE00-47E3-A76E-9C1087789C8FQ33764917-34170B8F-340B-4A59-8662-C5B9A66DDC60Q33786443-C7A5E624-3DBA-4207-9828-83A5FDC164CAQ33854841-A8C1A767-EA6B-4832-B31B-F3E49C9B8C83Q34059543-FB8D3FD1-36DA-4BCD-AC06-D255024573CAQ34114798-CD76AF65-BD55-4FBE-9C65-161385B445C6Q34177732-D5752D11-7DD4-4CF1-B544-5FC903E37B54Q34392963-1914DAA6-B713-4814-AB5D-31F542341A2FQ34527469-34013598-8D3D-43FB-8324-C8B3C9EDC85DQ34550046-3164532C-012A-4A13-8720-E248674C5818Q34593647-CB1CEB3E-0BF3-41BC-B07A-373AB3EA1B7FQ34594036-C703C879-8F39-429F-B9F1-E4E40CB55D18Q34594513-0685FF15-E1E8-48BC-A5B4-1629D47EBF17Q35007412-1321326D-1F7C-48B7-94A9-EDBCA8F3EA85Q35076748-63B8ABB8-7E98-4631-AAF5-CD1A361EB4CBQ35142291-8A57CAFE-8661-47A4-9FE7-5B9B8CA74DEBQ35592911-7E6B34C2-03C8-4597-AE86-00B34A8585E1Q35619402-7B0A34BD-99D8-4C38-9D39-41F4B93144EAQ35640998-32B069AD-2E9F-4D23-B3DD-77F70A979F2BQ35641369-78B32B47-C9BC-458E-BBF0-5C09DBF72EB7Q35674731-D43BEF2C-2AD5-4511-9522-B9E4FA8D9773Q35715634-16912C04-E66D-4831-A6B4-C8A3D6F91BC0Q35861256-D1F56294-2C97-4BB7-8469-99B6465D8593
P2860
Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.
@ast
Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.
@en
type
label
Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.
@ast
Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.
@en
prefLabel
Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.
@ast
Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.
@en
P2860
P50
P1433
P1476
Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.
@en
P2093
Michael S Seaman
Robert T Bailer
P2860
P304
P356
10.1097/QAD.0000000000000106
P407
P577
2014-01-01T00:00:00Z